MISTIE-III Mobile

This mobile application was created to facilitate enrollment into the MISTIE-III Clinical Trial. MISTIE-III is a five-year clinical trial designed to demonstrate the safety and long-term efficacy of thrombolysis in the treatment of intracerebral hemorrhage (ICH).

The primary hypothesis of this trial is to demonstrate that minimally invasive surgery (MIS) plus recombinant tissue plasminogen activator (rt-PA) for three days improves functional outcome by a 13% increase in the modified Rankin Scale (mRS) score 0-3 compared to medically treated subjects.